Derechos humanos y educación : retos de una nueva sociedad

[EU]Hitzaurrea (X. Etxague eta A. Lareki). - Giza Eskubideak eta gaitasunak derrigorrezko hezkuntzan: zeharkakotasunetik lantzeko proposamena (E. Cruz). - Giza Eskubideak eta adimen urritasuna duten pertsonak: Ordiziako Garaguneko esperientzia bat (J. F. Amiama). - Begirada bat Euskal Herriko haurrentzako eta gazteentzako aisia hezigarriari. Etengabe eraikitzen ari den eskubidea (J. Jiménez). - Informazioa eskuratzeko eskubidea landako eskoletan eta eskola unitarioetan (A. Fernández). - Gazteak sare sozialen bidez gizalegez sozializatzeko teoria politikoa helburu (E. Fernández eta J. M. Gutiérrez). - Komunikatzeko eskubidea eta pribatutasun eskubidea sarean: binomio kezkagarria 14 urtetik beherako seme alabak dituzten familientzat (J. Altuna). - Arimaren sufrimendua lausatzeko bertsoak (P. Pérez).

Prediction of Multi-Target Networks of Neuroprotective Compounds with Entropy Indices and Synthesis, Assay, and Theoretical Study of New Asymmetric 1,2-Rasagiline Carbamates

In a multi-target complex network, the links (L-ij) represent the interactions between the drug (d(i)) and the target (t(j)), characterized by different experimental measures (K-i, K-m, IC50, etc.) obtained in pharmacological assays under diverse boundary conditions (c(j)). In this work, we handle Shannon entropy measures for developing a model encompassing a multi-target network of neuroprotective/neurotoxic compounds reported in the CHEMBL database. The model predicts correctly >8300 experimental outcomes with Accuracy, Specificity, and Sensitivity above 80%-90% on training and external validation series. Indeed, the model can calculate different outcomes for >30 experimental measures in >400 different experimental protocolsin relation with >150 molecular and cellular targets on 11 different organisms (including human). Hereafter, we reported by the first time the synthesis, characterization, and experimental assays of a new series of chiral 1,2-rasagiline carbamate derivatives not reported in previous works. The experimental tests included: (1) assay in absence of neurotoxic agents; (2) in the presence of glutamate; and (3) in the presence of H2O2. Lastly, we used the new Assessing Links with Moving Averages (ALMA)-entropy model to predict possible outcomes for the new compounds in a high number of pharmacological tests not carried out experimentally.